Hong Kong, April 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2).
The notification does not immediately affect the listing or trading of the company’s shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until 14 October 2025, to regain compliance with the continued listing requirements.
During this period, Aptorum Group Limited intends to evaluate all available options to restore compliance, including, if necessary, a reverse stock split. The company is committed to maintaining its Nasdaq listing and will take all reasonable measures to achieve compliance within the stipulated time frame.
About Aptorum Group Limited
Aptorum Group Limited is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. These statements reflect the company’s current expectations and projections about future events and are based on assumptions. Actual results may differ materially from those projected.
For further information, please contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.80 |
Daily Change: | -0.05 -2.70 |
Daily Volume: | 94,692 |
Market Cap: | US$9.630M |
September 05, 2025 August 21, 2025 December 20, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load